DENGUE FEVER: STAGES, COMPLICATION, DIAGNOSIS, AND PREVENTION STRATEGIES

  • POULOMI BISWAS Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India.
  • SANTOSH GANGULY Department of Pharmaceutics, Bharat Pharmaceutical Technology, Agartala, Tripura, India.
  • BIPLAB DEBNATH Department of Pharmacy, Bharat Technology, Uluberia, West Bengal, India.

Abstract

Dengue fever virus (DENV) is said to be a single-stranded, positive-sense RNA virus that belongs to the family Flaviviridae and the genus is Flavivirus. The disease can be transmitted through infected blood products and also through organ donation. Vertical transmission (from mother to child) at the time of pregnancy or during birth has been reported. Other unusual reports showed man-to-man modes of transmission. Hemorrhagic fever is specified by hemorrhage, thrombocytopenia, leakage of blood plasma, or dengue shock syndrome. Dengue is basically transmitted by various species of mosquito among the genus Aedes, the most uniquely identified one is Aedes aegypti. There are four different but very closely related serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) of the virus that causes Dengue. Lifelong immunity against the particular serotype that has caused the infection is believed to have been imparted upon recovery. However, cross-immunity to the other serotypes is either partial or temporary upon recovery and hence future infections by any of the other serotypes enhance the risk of developing severe dengue. Prevention is identified by reducing the habitat and the number of mosquitoes and also by limiting exposure to bites. Treatment of mild or moderate type is supportive, with oral or intravenous rehydration. The intravenous fluids and blood transfusion for more severe cases are found to be effective. The present study aimed to present brief and informative salient features of various facts regarding dengue, including its global incidence, structure, mode of transmission, clinical signs and symptoms, control, and preventive measures.

Keywords: Dengue, Serotypes, Cross-immunity, Transmission, Complications, Prevention

References

1. Scott H. Recent advances in understanding. F1000Res 2019;8:1-12.
2. Heilman JM, De Wolff J, Beards GM, Basden BJ. Dengue fever: A Wikipedia clinical review. Open Med 2014;8:e105-15.
3. Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev 1990;3:376-96.
4. Azad S, Lio P. Emerging trends of malaria-dengue geographical coupling in the Southeast Asia region. J Vector Borne Dis 2014;51:165-71.
5. Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of dengue in Southeast Asia. PLoS Negl Trop Dis 2013;7:e2055.
6. Karyanti MR, Uiterwaal CS, Kusriastuti R, Hadinegoro SR, Rovers MM, Heesterbeek H, et al. The changing incidence of dengue haemorrhagic fever in Indonesia: A 45-year registry-based analysis. BMC Infect Dis 2014;14:412.
7. Aiken SR, Leigh CH. Dengue haemorrhagic fever in South-east Asia. Trans Inst Br Geogr 1978;3:476-97.
8. Lia RA, Lutfan L, Yien LH, Asa H, Kusnanto H, Rocklöv J. Prediction of dengue outbreaks based on disease surveillance and meteorological data. PLoS One 2016;11:1-18.
9. World Health Organization. Comprehensive Guideline for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. Geneva: World Health Organization, Regional Office for South-East Asia; 2011.
10. Juffrie M, Focks DA. Early warning system (EWS) for dengue in Indonesia and Thailand. Berkala IlmuKedokteran 2009;41:134-42.
11. Indriani C, Fuad A, Kusnanto H. Spatial-temporal pattern comparison between chikungunya outbreak and dengue hemmorhagis fever incidence at Kota Yogyakarta 2008. Ber Kedokt Masy 2011;27:41-50.
12. Hii YL, Rocklöv J, Wall S, Ng LC, Tang CS, Ng N. Optimal lead time for dengue forecast. PLoS Negl Trop Dis 2012;6:e1848.
13. Lambrechts L, Scott TW, Gubler DJ. Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl Trop Dis 2010;4:e646.
14. Reiter P. Aedes albopictus and theworld trade in used tires, 1988-1995: The shape of things to come? J Am Mosq Control Assoc 1998;14:83-94.
15. Schwartz E, Weld LH, Wilder-Smith A, von Sonnenburg F, Keystone JS, Kain KC, et al. Seasonality, annual trends, andcharacteristics of dengue among ill returned travelers, 1997-2006. Emerg Infect Dis 2008;14:1081-8.
16. Ashburn PM, Craig CF. Experimental investigations regarding the etiology of dengue fever. J Infect Dis 1907;4:440-75.
17. Vaddadi S, Vaddadi SR. Dengue fever: A review article. J Evol Med Dent Sci 2015;4:5048-58.
18. Gubler DJ. The global pandemic of dengue/dengue haemorrhagic fever: Current status and prospects for the future. Ann Acad Med Singapore 1998;27:227-34.
19. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998;11:480-96.
20. Gubler DJ. Dengue and dengue hemorrhagic fever in the Americas. P R Health Sci J 1987;6:107-11.
21. National Vectorborne Disease Control Program, Directorate General of Health Services. Available from: http://www.nvbdcp.gov.in/ DENGU1.html.
22. National Centre for Disease Control, Directorate General of Health Services. Integrated Disease Surveillance Program: Diseases under Surveillance. Available from: http://www.idsp.nic.in/showfile. php?lid=3923.
23. Department of Health Research, Govt of India. Establishment of a Network of Laboratories for Managing Epidemics and Natural Calamities. Available from: http://www.dhr.gov.in/schemes/ establishment-networklaboratories-managing-epidemics-and-natural-calamities.
24. Gubler DJ. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: Top down or bottom up. Charles franklin Craig lecture. Am J Trop Med Hyg 1989;40:571-8.
25. Pinheiro FP, Corber SJ. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. World Health Stat Q 1997;50:161-9.
26. Rodier G, Gubler DJ, Cope SE, Bercion R, Cropp CB, Soliman AK, et al. Epidemic dengue in the city of Djibouti, Horn of Africa. Trans R Soc Trop Med Hyg 1991-1992;90:237-40.
27. Gubler DJ, Clark GG. Dengue/dengue hemorrhagic fever: The emergence of a global health problem. Emerg Infect Dis 1995;1:55-7.
28. Malavige GN, Fernando S, Fernando DJ, Seneviratne SL. Dengue viral infections. Postgrad Med J 2004;80:588-601.
29. Rezza G. Aedes albopictus and the re-emergence of dengue. BMC Public Health 2012;12:1-3.
30. Westaway EG, Blok J. Taxonomy and evolutionary relationships of flaviviruses. In: Gubler DJ, Kuno G, editors. Dengueand Dengue Hemorrhagic Fever. London, United Kingdom: CAB International; 1997. p. 147-73.
31. Duane JG. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998;11:480-96.
32. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: Anintegrated view. Clin Microbiol Rev 2009;22:564-81.
33. World Health Organization. Dengue: Guidelines for diagnosis, treatment, prevention and control. In: Epidemiology, Burden of Disease and Transmission. Ch. 1. Geneva, Switzerland: World Health Organization; 2009. p. 3-21.
34. World Health Organization. Global strategy for dengue prevention and control 2012-2020. In: Part 3.3: Sustainable Vector Control. Geneva, Switzerland: World Health Organization; 2012.
35. Chen LH, Wilson ME. Dengue and chikungunya infections in travelers. Curr Opin Infect Dis 2010;23:438-44.
36. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: A continuing global threat. Nat Rev Microbiol 2010;8:S7-16.
37. Rodenhuis-Zybert IA, Wilschut J, Smit JM. Dengue virus life cycle: Viral and host factors modulating infectivity. Cell Mol Life Sci 2010;67:2773-86.
38. Simmons CP, Farrar JJ, Nguyen vV, Wills B. Dengue. N Engl J Med 2012;366:1423-32.
39. Molina-Cruz LA, Gupta J, Richardson K, Bennett W, Barillas-Mury C. Effect of mosquito midgut trypsin activity on dengue-2 virus infection and dissemination in Aedes aegypti. Am J Trop Med Hyg 2005;72:631-7.
40. Narvaez F, Gutierrez G, Pérez MA, Elizondo D, Nuñez A, Balmaseda A, et al. Evaluation of the traditional and revised WHO classifications of dengue disease severity. PLoS Negl Trop Dis 2011;5:e1397.
41. Cameron PS, Jeremy JF, Nguyen C, Bridget W. Current concepts dengue. N Engl J Med 2012;366:1423-32.
42. Wichmann O, Hongsiriwon S, Bowonwatanuwong C, Chotivanich K, Sukthana Y, Pukrittayakamee S. Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Trop Med Int Health 2004;9:1022-9.
43. Nguyet MN, Duong TH, Trung VT, Nguyen TH, Tran CN, Long VT, et al. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc Natl Acad Sci U S A 2013;110:9072-7.
44. World Health Organization. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva, Switzerland: World Health Organization; 2009.
45. Varatharaj A. Encephalitis in the clinical spectrum of dengue infection. Neurol India 2010;58:585-91.
46. Gould EA, Solomon T. Pathogenic flaviviruses. Lancet 2008;371:500-9.
47. Ranjit S, Kissoon N. Dengue hemorrhagic fever and shock syndromes. Pediatr Crit Care Med 2011;12:90-100.
48. Gubler DJ, Sather GE. Laboratory diagnosis of dengue and dengue hemorrhagic fever. In: Homma A, Cunha JF, editors. Proceedings of the International Symposium on Yellow Fever and Dengue; 1988. p. 291-322.
49. Guzman MG, Kouri G. Advances in dengue diagnosis. Clin Diagn Lab Immunol 1996;3:621-7.
50. Hammon WM, Rudnick A, Sather G. New hemorrhagic fevers of children in the Philippines and Thailand. Trans Assoc Am Physicians 1960;73:140-55.
51. Vorndam V, Kuno G. Laboratory diagnosis of dengue virusinfections. In: Gubler DJ, Kuno G, editor. Dengue Adengue Hemorrhagic Fever-1997. London, United Kingdom: CAB International; 1997. p. 313-34.
52. Yuill TM, Sukkhavachana P, Nisalak A, Russell PK. Dengue-virus recovery by direct and delayed plagues in LLC-MK2 cells. Am J Trop Med Hyg 1968;17:441-8.
53. Rosen L, Gubler DJ. The use of mosquitoes to detect and propagate dengue viruses. Am J Trop Med Hyg 1974;21:1153-60.
54. Gubler DJ, Suharyono W, Sumarmo H, Jahja WE, Saroso JS. Virological surveillance for dengue haemorrhagic fever in Indonesia using the mosquito inoculation technique. Bull World Health Organ 1979;57:931-6.
55. Gubler DJ, Reed D, Rosen L, Hitchcock JR Jr. Epidemiologic, clinical and virologic observations on dengue in the Kingdom of Tonga. Am J Trop Med Hyg 1978;27:581-9.
56. Lam SK, Chew CB, Poon GK, Ramalingam S, Seow SC, Pang T. Isolation of dengue viruses by intracerebral inoculation of mosquito larvae. J Virol Methods 1986;14:133-40.
57. Thet-Win . Detection of dengue virus by immunofluorescence after intracerebral inoculation of mosquitoes. Lancet 1982;1:53-4.
58. Kuberski TT, Rosen L. A simple technique for the detection of dengue antigen in mosquitoes by immunofluorescence. Am J Trop Med Hyg 1977;26:533-7.
59. Sumarmo SP, Wulur H, Jahja E, Gubler DJ. Clinical observations on virologically confirmed fatal dengue infections in Jakarta, Indonesia. Bull World Health Organ 1983;61:693-701.
60. Gubler DJ, Kuno G, Sather GE, Velez M, Oliver A. Use of mosquito cell cultures and specific monoclonal antibodies for routine surveillance of dengue viruses. Am J Trop Med Hyg 1984;33:158-65.
61. Kuno G, Gubler DJ, Velez M, Oliver A. Comparative sensitivity of three mosquito cell lines for isolation of dengue viruses. Bull World Health Organ 1985;63:279-86.
62. Igarashi A. Isolation of Singh’s Aedes albopictus cell clone sensitiveto dengue and chikungunya viruses. J Gen Virol 1978;40:530-44.
63. Tesh RB. A method for the isolation and identification of dengueviruses, using mosquito cell cultures. Am J Trop Med Hyg 1979;28:1053-9.
64. Varma MG, Pudney M. The growth and serial passage of cell lines from Aedes aegypti (L.) larvae in different media. J Med Entomol 1969;6:432-9.
65. Gubler DJ, Sather GE, Kuno G, Cabral JR. Dengue 3 virus transmission in Africa. Am J Trop Med Hyg 1986;35:1280-4.
66. Gubler DJ. Dengue/dengue hemorrhagic fever: The emergence of a global health problem. Emerg Infect Dis 1995;1:55-7.
67. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue in the early febrile phase: Viremia and antibody responses. J Infect Dis 1997;176:322-30.
68. Henchal EA, McCown JM, Sequin MC, Gentry MK, Brandt WE. Rapid identification of dengue virus isolates by using monoclonal antibodies in an indirect immunofluorescence assay. Am J Trop Med Hyg 1983;32:164-9.
69. Gubler DJ, Kuno G, Sather GE, Waterman SH. A case of natural concurrent human infection with two dengue viruses. Am J Trop Med Hyg 1985;34:170-3.
70. Laille M, Deubel V, Sainte-Marie FF. Demonstration of concurrent dengue 1 and dengue 3 infection in six patients by the polymerase chain reaction. J Med Virol 1991;34:51-4.
71. Gubler DJ, Suharyono W, Tan R, Abidin M, Sie A. Viremia in patients with naturally acquired dengue infection. Bull World Health Organ 1981;59:623-30.
72. Dietz V, Gubler DJ, Ortiz S, Kuno G, Casta-Velez A, Sather GE, et al. The 1986 dengue and dengue hemorrhagic fever epidemic in Puerto Rico: Epidemiologic and clinical observations. P R Health Sci J 1996;15:201-10.
73. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue viruses from clinical samples using reverse transcriptase chain reaction. J Clin Microbiol 1992;30:545-51.
74. Deubel V. The contribution of molecular techniques to the diagnosis of dengue infection. In: Gubler DJ, Kuno G, editors. Dengue and Dengue Hemorrhagic Fever. London, United Kingdom: CAB International; 1997. p. 335-66.
75. Deubel V, Pierre V. Molecular techniques for rapid and moresensitive detection and diagnosis of flaviviruses. In: Spencer RC, Wright EP, Newsom SW, editors. Rapid Methods and Automation in Microbiology and Immunology. United Kingdom: Intercept, Andover; 199. p. 227-37.
76. Hall WC, Crowell TP, Watts DM, Barros VL, Kruger H, Pinheiro F, et al. Demonstration of yellow fever and dengueantigens in formalin-fixed paraffin embedded human liver by immunohistochemical analysis. Am J Trop Med Hyg 1991;45:408-17.
77. World Health Organization. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. Vol. 3. Geneva, Switzerland: World Health Organization; 2009. p. 59.
78. Guzman GM. Dengue: A continuing global threat. Nat Rev Microbiol 2010;8:S7-16.
79. Maciel-de-Freitas R, Avendanho FC, Santos R, Sylvestre G, Araujo SC, Lima JB, et al. Undesirable consequences of insecticide resistance following Aedes aegypti control activities due to a dengue outbreak. PLoS One 2014;9:e92424.
80. Ramkumar G, Karthi S, Muthusamy R, Natarajan D, Shivakumar MS. Adulticidal and smoke toxicity of Cipadessa baccifera (Roth) plant extracts against Anopheles stephensi, Aedes aegypti, and Culex quinquefasciatus. Parasitol Res 2015;114:167-73.
81. Marcombe S, Chonephetsarath S, Thammavong P, Brey PT. Alternative insecticides for larval control of the dengue vector Aedes aegypti in Lao PDR: Insecticide resistance and semifield trial study. Parasit Vectors 2018;11:616.
82. Pierre DY. Okechukwu EC, Nchiwan NE. Larvicidal and phytochemical properties of Callistemon rigidus R. Br. (Myrtaceae) leaf solvent extracts against three vector mosquitoes. J Vector Borne Dis 2014;51:216-23.
83. Reiter P. Yellow fever and dengue: A threat to Europe? Euro Surveill 2010;15:19509.
84. Olson KAL, Carlson J, James A. Genetic Approaches in Aedesa egypti for Control of Dengue. The Netherlands: Springer; 2006. p. 77-87.
85. Mishra A, Ambrosio B, Gakkhar S, Aziz-Alaoui MA. A network model for control of dengue epidemic using sterile insect technique. Math Biosci Eng 2018;15:441-60.
86. Werren JH, Baldo L, Clark ME. Wolbachia: Master manipulators of invertebrate biology. Nat Rev Microbiol 2008;6:741-51.
87. Kitrayapong P, Baimai V, O’Neill SL. Field prevalence of Wolbachia in the mosquito vector Aedes albopictus. Am J Trop Med Hyg 2002;66:108-11.
88. Tchankouo-Nguetcheu S, Khun H, Pincet L, Roux P, Bahut M, Huerre M, et al. Differential protein modulation in midguts of Aedes aegypti infected with chikungunya and dengue 2 viruses. PLoS One 2010;5:e13149.
89. Dostert C, Jouanguy E, Irving P, Troxler L, Galiana-Arnoux D, Hetru C, et al. The Jak-STAT signaling pathway is required but not sufficient for the antiviral response of drosophila. Nat Immunol 2005;6:946-53.
90. McMeniman CJ, Lane RV, Cass BN, Fong AW, Sidhu M, Wang YF, et al. Stable introduction of a life-shortening Wolbachia infection into the mosquito Aedes aegypti. Science 2009;323:141-4.
91. Wilder-Smith A, Chen LH, Massad E, Wilson ME. Threat of dengue to blood safety in dengue-endemic countries. Emerg Infect Dis 2009;15:8-11.
92. Normile D. Tropical medicine. Surprising new dengue virus throws a spanner in disease control efforts. Science 2013;342:415.
93. Xie X, Zou J, Wang QY, Shi PY. Targeting dengue virus NS4B protein for drug discovery. Antiviral Res 2015;118:39-45.
94. Behnam MA, Nitsche C, Boldescu V, Klein CD. The medicinal chemistry of dengue virus. J Med Chem 2016;59:5622-49.
95. Hombach J. Vaccines against dengue: A review of current candidate vaccines at advanced development stages. Rev Panam Salud Publica 2007;21:254-60.
96. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015;373:1195-206.
97. World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2016 conclusions and recommendations? Wkly Epidemiol Rec 2016;91:266-84.
98. Nascimento EJ, George JK, Velasco M, Bonaparte MI, Zheng L, DiazGranados CA, et al. Development of an anti-dengueNS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods 2018;257:48-57.
99. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med 2018;379:327-40.
100. World Health Organization. Dengue vaccine: WHO position paper September? Wkly Epidemiol Rec 2018;93:457-76.
101. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 2012;380:1559-67.
102. Juraska M, Magaret CA, Shao J, Carpp LN, Fiore-Gartland AJ, Benkeser D, et al. Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. Proc Natl Acad Sci U S A 2018;115:E8378-87.
103. Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, et al. Mapping the human memory B cell and serum neutralizing antibody responses to dengue virus serotype 4 infection and vaccination. J Virol 2017;91:e02041-16.
104. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: A chimericdengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011;29:7251-60.
105. Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N, et al. Chimeric dengue Type 2 (vaccine strain PDK-53)/dengue Type 1 virus as a potential candidate dengue Type 1 virusvaccine. J Virol 2000;74:3020-8.
106. Vaughn DW, Hoke CH Jr., Yoksan S, LaChance R, Innis BL, Rice RM, et al. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 1996;14:329-36.
107. Durbin AP, Whitehead SS. Next-generation dengue vaccines: Novel strategies currently under development. Viruses 2011;3:1800-14.
108. Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? Expert Rev Vaccines 2016;15:509-17.
109. Durbin AP, Kirkpatrick BD, Pierce KK, et al. A 12-month-interval dosing studyin adults indicates that a single dose of the national institute of allergy andinfectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. J Infect Dis 2016;214:832-35.
110. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, et al. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis 2013;207:1898-908.
Statistics
51 Views | 114 Downloads
Citations
How to Cite
BISWAS, P., S. GANGULY, and B. DEBNATH. “DENGUE FEVER: STAGES, COMPLICATION, DIAGNOSIS, AND PREVENTION STRATEGIES”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 5, May 2021, pp. 3-11, doi:10.22159/ajpcr.2021.v14i5.40960.
Section
Review Article(s)